Anti-complement Factor H (CFH) Autoantibodies Could Delay Pristane-induced Lupus Nephritis

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2023 Jun 15

PMID 37322353

Authors

Lin-Lin Li

Zhong-Qiu Luan

Ying Tan

Hui Wang

Xiao-Juan Yu

Zhen Qu

Feng Yu

Min Chen

Affiliations

Soon will be listed here.

Abstract

Purpose: Anti-complement factor H (CFH) autoantibodies could be detected in lupus and its significance remained to be elucidated. Herein, we aimed to explore the roles of anti-CFH autoantibodies based on pristane-induced lupus mice.

Methods: Twenty-four female Balb/c mice were randomly divided into four groups, with one group injected with pristane (pristane group), one group with pristane and then human CFH (hCFH) (pristane-CFH group) 3 times, and the other two as vertical controls, PBS group and PBS-CFH group. Histopathological analysis was performed six months after pristane administration. Levels of hCFH, anti-CFH autoantibodies and anti-dsDNA antibody were detected. Murine IgG (mIgG) were purified and cross-reactivity, epitopes, subclasses and functional analysis were further evaluated in vitro.

Results: Immunization with hCFH and subsequent development of anti-CFH autoantibodies significantly attenuated nephritis of pristane-induced lupus, including lower levels of urinary protein and serum creatinine, decreased levels of serum anti-dsDNA antibody, greatly ameliorated renal histopathologic damage, decreased IgG, complements (C1q, C3) deposits and lower inflammatory factor (IL-6) expression in glomerulus. Furthermore, the purified mIgG (contained anti-CFH autoantibodies) could recognize both hCFH and murine CFH, and the epitopes were predominantly located in hCFH short consensus repeats (SCRs) 1-4, 7 and 11-14. The IgG subclasses were predominant IgG1. The autoantibodies could enhance the binding between hCFH and C3b, and increase factor I mediated-C3b lysis in vitro.

Conclusion: Our results suggested that anti-CFH autoantibodies could attenuate pristane-induced lupus nephritis by increasing bio-functions of CFH on regulating complement activation and controlling inflammation.

References

Chun H, Chung J, Kim H, Yun J, Jeon J, Ye Y . Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27(5):461-6. DOI: 10.1007/s10875-007-9104-0. View

Wang F, Yu F, Zhao M . A method of purifying intact complement factor H from human plasma. Protein Expr Purif. 2013; 91(2):105-11. DOI: 10.1016/j.pep.2013.07.014. View

Guo W, Song D, Liu X, Chen Z, Xiao H, Ding J . Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome. Pediatr Nephrol. 2018; 34(2):269-281. DOI: 10.1007/s00467-018-4074-4. View

Rahbar Saadat Y, Hejazian M, Bastami M, Hosseinian Khatibi S, Ardalan M, Zununi Vahed S . The role of microbiota in the pathogenesis of lupus: Dose it impact lupus nephritis?. Pharmacol Res. 2018; 139:191-198. DOI: 10.1016/j.phrs.2018.11.023. View

Wang H, Xu J, Zhang X, Ren Y, Cheng M, Guo Z . Tubular basement membrane immune complex deposition is associated with activity and progression of lupus nephritis: a large multicenter Chinese study. Lupus. 2017; 27(4):545-555. DOI: 10.1177/0961203317732407. View

Bao L, Haas M, Quigg R . Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2010; 22(2):285-95. PMC: 3029901. DOI: 10.1681/ASN.2010060647. View

Kuhn S, Zipfel P . Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur J Immunol. 1996; 26(10):2383-7. DOI: 10.1002/eji.1830261017. View

Michael M, Elliott E, Ridley G, Hodson E, Craig J . Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev. 2009; (1):CD003595. PMC: 7154575. DOI: 10.1002/14651858.CD003595.pub2. View

Foltyn Zadura A, Zipfel P, Bokarewa M, Sturfelt G, Jonsen A, Nilsson S . Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther. 2012; 14(4):R185. PMC: 3580581. DOI: 10.1186/ar4016. View

10.

Kiberd B . Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol. 1993; 4(1):58-61. DOI: 10.1681/ASN.V4158. View

11.

Szyper Kravitz M, Pitashny M, Shoenfeld Y . Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol. 2005; 25(6):582-91. DOI: 10.1007/s10875-005-7828-2. View

12.

Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X . Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022; 132:102871. DOI: 10.1016/j.jaut.2022.102871. View

13.

Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan K, George S . Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006; 35(3-4):148-53. DOI: 10.1016/j.cyto.2006.07.023. View

14.

Colliard S, Jourde-Chiche N, Clavarino G, Sarrot-Reynauld F, Gout E, Deroux A . Autoantibodies Targeting Ficolin-2 in Systemic Lupus Erythematosus Patients With Active Nephritis. Arthritis Care Res (Hoboken). 2017; 70(8):1263-1268. DOI: 10.1002/acr.23449. View

15.

Li L, Tan Y, Song D, Li Y, Yu F, Chen M . Anti-complement factor H autoantibodies may be protective in lupus nephritis. Clin Chim Acta. 2020; 508:1-8. DOI: 10.1016/j.cca.2020.05.005. View

16.

Birmingham D, Bitter J, Ndukwe E, Dials S, Gullo T, Conroy S . Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. Clin J Am Soc Nephrol. 2015; 11(1):47-53. PMC: 4702227. DOI: 10.2215/CJN.03990415. View

17.

Lucientes-Continente L, Marquez-Tirado B, Goicoechea de Jorge E . The Factor H protein family: The switchers of the complement alternative pathway. Immunol Rev. 2022; 313(1):25-45. PMC: 10099856. DOI: 10.1111/imr.13166. View

18.

Zeggar S, Watanabe K, Teshigawara S, Hiramatsu S, Katsuyama T, Katsuyama E . Role of Lgals9 Deficiency in Attenuating Nephritis and Arthritis in BALB/c Mice in a Pristane-Induced Lupus Model. Arthritis Rheumatol. 2018; 70(7):1089-1101. DOI: 10.1002/art.40467. View

19.

Yaniv G, Twig G, Ben-Ami Shor D, Furer A, Sherer Y, Mozes O . A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev. 2014; 14(1):75-9. DOI: 10.1016/j.autrev.2014.10.003. View

20.

Bao L, Cunningham P, Quigg R . Complement in Lupus Nephritis: New Perspectives. Kidney Dis (Basel). 2016; 1(2):91-9. PMC: 4934819. DOI: 10.1159/000431278. View